Clinical Trial Detail

NCT ID NCT01722162
Title Levocetirizine + Capecitabine + Bevacizumab for Patients With Refractory Colorectal Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements no
Sponsors Washington University School of Medicine
Indications

colorectal cancer

Therapies

Bevacizumab + Capecitabine

Age Groups: adult

No variant requirements are available.